Liquid biopsy enters the clinic—implementation issues and future challenges
M Ignatiadis, GW Sledge, SS Jeffrey - Nature reviews Clinical oncology, 2021 - nature.com
Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …
cells in peripheral blood have provided crucial insights into cancer biology and the …
[HTML][HTML] Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
Metastatic progression is the main cause of death in cancer patients, whereas the
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
underlying genomic mechanisms driving metastasis remain largely unknown. Here, we …
Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE biopharma collaborative in cBioPortal
International cancer registries make real-world genomic and clinical data available, but their
joint analysis remains a challenge. AACR Project GENIE, an international cancer registry …
joint analysis remains a challenge. AACR Project GENIE, an international cancer registry …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
Tumor mutational burden as a predictive biomarker in solid tumors
Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent
inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small …
inhibitor of KRASG12C. We report results from a phase I/IB study of adagrasib in non–small …
Metastatic colorectal cancer: mechanisms and emerging therapeutics
AE Shin, FG Giancotti, AK Rustgi - Trends in pharmacological sciences, 2023 - cell.com
Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …
A targetable LIFR− NF-κB− LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
The growing knowledge of ferroptosis has suggested the role and therapeutic potential of
ferroptosis in cancer, but has not been translated into effective therapy. Liver cancer …
ferroptosis in cancer, but has not been translated into effective therapy. Liver cancer …
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
Only a fraction of patients with cancer respond to immune checkpoint blockade (ICB)
treatment, but current decision-making procedures have limited accuracy. In this study, we …
treatment, but current decision-making procedures have limited accuracy. In this study, we …
[HTML][HTML] Ovarian cancer mutational processes drive site-specific immune evasion
High-grade serous ovarian cancer (HGSOC) is an archetypal cancer of genomic instability,,–
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …
patterned by distinct mutational processes,, tumour heterogeneity,–and intraperitoneal …